{"id":533341,"date":"2021-03-09T11:52:01","date_gmt":"2021-03-09T11:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=533341"},"modified":"2021-03-09T11:52:01","modified_gmt":"2021-03-09T11:52:01","slug":"attention-deficit-hyperactivity-disorder-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/attention-deficit-hyperactivity-disorder-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_533341.html","title":{"rendered":"Attention deficit hyperactivity disorder Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1615264334.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Attention deficit hyperactivity disorder Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1615264334.jpeg\" alt=\"Attention deficit hyperactivity disorder Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Attention Deficit Hyperactivity Disorder Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s<strong> &#8220;<\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Attention deficit hyperactivity disorder Market<\/a><\/strong><strong> Insights, Epidemiology, and Market Forecast-2030<\/strong><strong>&#8220;<\/strong><strong>&nbsp;<\/strong>report delivers an in-depth understanding of the Attention-deficit\/hyperactivity disorder (ADHD), historical and forecasted epidemiology as well as the Attention-deficit\/hyperactivity disorder (ADHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Attention Deficit Hyperactivity Disorder facts<\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total market size for Attention Deficit Hyperactivity Disorder was&nbsp;<strong>USD 15,094<\/strong>&nbsp;Million in&nbsp;<strong>2016<\/strong><\/li>\n<li>The&nbsp;<strong>US<\/strong>&nbsp;has the highest number of cases, followed by&nbsp;Japan&nbsp;and other European countries.<\/li>\n<li><strong>France<\/strong>&nbsp;had the highest diagnosed prevalent population of ADHD with&nbsp;<strong>2,376,591<\/strong>&nbsp;cases,<\/li>\n<li>Japan&nbsp;had&nbsp;<strong>3,122,705<\/strong>&nbsp;diagnosed prevalent cases of ADHD.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Attention Deficit Hyperactivity Disorder Companies<\/strong><strong> covered<\/strong>:<\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Shire<\/li>\n<li>Hisamitsu Pharmaceutical Co<\/li>\n<li>Neos Therapeutics<\/li>\n<li>Rhodes Pharmaceuticals<\/li>\n<li>Tris Pharma<\/li>\n<li>Highland Therapeutics<\/li>\n<li>Supernus Pharmaceuticals<\/li>\n<li>Aevi Genomic Medicine<\/li>\n<li>Sumitomo Dainippon Pharma<\/li>\n<li>Kempharm<\/li>\n<li>NLS Pharma<\/li>\n<li>RespireRx Pharmaceuticals<\/li>\n<li>Ostuka Pharmaceuticals<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Attention Deficit Hyperactivity Disorder Report<\/strong><strong> Highlights:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Attention-deficit\/hyperactivity disorder (ADHD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Attention-deficit\/hyperactivity disorder (ADHD) epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Attention-deficit\/hyperactivity disorder (ADHD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Attention-deficit\/hyperactivity disorder (ADHD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Attention-deficit\/hyperactivity disorder (ADHD) market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Attention deficit hyperactivity disorder<\/a><\/strong><strong> (ADHD)<\/strong> is a brain disorder marked by an ongoing pattern of inattention and\/or hyperactivity-impulsivity that interferes with functioning or development. ADHD is a group of behaviors and is also called as attention deficit disorder (ADD). ADHD is a behavioral disorder that includes symptoms such as inattentiveness, hyperactivity, and impulsiveness.<\/p>\n<p style=\"text-align: justify;\">Symptoms of ADHD tend to be noticed at an early age and may become more noticeable when a child&#8217;s circumstances change, such as when they start school. Most cases are diagnosed when children are 6 to 12 years old. The symptoms of ADHD usually improve with age, but many adults who were diagnosed with the condition at a young age continue to experience problems. People with ADHD may also have additional problems, such as sleep and anxiety disorders.<\/p>\n<p style=\"text-align: justify;\">According to a study conducted by Guifeng et al. titled &ldquo;Twenty-Year Trends in Diagnosed Attention-Deficit\/Hyperactivity Disorder among US Children and Adolescents, 1997&ndash;2016,&rdquo; published in 2018, estimated the prevalence of diagnosed attention-deficit\/hyperactivity disorder increased significantly between 1997 and 2016. It has also been observed that the prevalence in children varied between 7.7% and 13.5%.<\/p>\n<p style=\"text-align: justify;\">Subtype-specific diagnosed prevalence of ADHD is divided into various types such as Inattentive; Hyperactive\/impulsive; combined. As per DelveInsight estimates, the diagnosed prevalence of combined type of ADHD was found to be highest in the United States.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Attention Deficit Hyperactivity Disorder Drugs<\/strong><strong> covered<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Vyvanse<\/li>\n<li>Mydayis<\/li>\n<li>Daytrana<\/li>\n<li>Adzenys<\/li>\n<li>Cotempla XR-ODT<\/li>\n<li>Aptensio XR<\/li>\n<li>Dyanavel XR<\/li>\n<li>Jornay<\/li>\n<li>SPN-812<\/li>\n<li>SPN-810<\/li>\n<li>AEVI-001\/ AEVI-004<\/li>\n<li>Dasotraline (SEP-225289)<\/li>\n<li>KP415<\/li>\n<li>NLS-1<\/li>\n<li>CX717<\/li>\n<li>Centanafadine<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/attention-deficit-hyperactivity-disorder-adhd-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Attention-deficit\/hyperactivity disorder (ADHD)<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Attention-deficit\/hyperactivity disorder (ADHD)<\/p>\n<p style=\"text-align: justify;\">4. Attention-deficit\/hyperactivity disorder (ADHD): Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Attention-deficit\/hyperactivity disorder (ADHD): Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Attention-deficit\/hyperactivity disorder (ADHD) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Attention-deficit\/hyperactivity disorder (ADHD) Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Attention-deficit\/hyperactivity disorder (ADHD): Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Attention-deficit\/hyperactivity disorder (ADHD)<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=attention-deficit-hyperactivity-disorder-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/attention-deficit-hyperactivity-disorder-adhd-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=attention-deficit-hyperactivity-disorder-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Attention Deficit Hyperactivity Disorder Market DelveInsight&#8217;s &#8220;Attention deficit hyperactivity disorder Market Insights, Epidemiology, and Market Forecast-2030&#8220;&nbsp;report delivers an in-depth understanding of the Attention-deficit\/hyperactivity disorder (ADHD), historical and forecasted epidemiology as well as the Attention-deficit\/hyperactivity disorder (ADHD) market trends in the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/attention-deficit-hyperactivity-disorder-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_533341.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-533341","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=533341"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533341\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=533341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=533341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=533341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}